Navigation Links
N30 Pharma Announces Presentation of Preclinical Data at the Basic Science Meeting of the European Cystic Fibrosis Society
Date:4/2/2013

, particularly the lung. 

About N30 Pharmaceuticals, Inc.N30 Pharma is a privately held, clinical stage, biopharmaceutical company headquartered in Boulder, Colorado. It is the first company to discover and develop small molecules targeting GSNOR.  N30 Pharma is conducting a clinical trial of its lead compound, N6022 (an injectable formulation) in patients with two copies of the F508del mutation.  In parallel, the company is rapidly advancing an oral dosage form, N91115, through preclinical testing and plans to begin clinical trials of N91115 in the first half of 2014.

N30 Pharma is dedicated to making a difference in the lives of patients with cystic fibrosis and their families.  Contacts:email info@N30Pharma.comSherif Gabriel

Charles Scoggin, MDVP, Research and Discovery

President and CEO(720) 945 7709

(720) 945 7721


'/>"/>
SOURCE N30 Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Everyday Health Expands Solutions For Pharmaceutical Industry Marketers
2. Pharmagen Announces Year-End Financial Results
3. DelMar Pharmaceuticals to Present Clinical Data from VAL-083 Brain Cancer Trial at the American Association of Cancer Research Annual Meeting
4. Valeant Pharmaceuticals Announces Private Exchange Offer
5. Pull-Through Programs Critical for Maintaining Demand for Pharmaceutical Products on Managed Care Formularies
6. Edison Pharmaceuticals, Inc. signs licensing agreement with Dainippon Sumitomo Pharma Co., Ltd. for development & commercialization of orphan mitochondrial and adult central nervous system disease drugs
7. Consumer Reports: So Many Drugstores, So Many Prices; New Report Finds Price Mayhem At The Pharmacy
8. Inovio Pharmaceuticals to Present at BioCenturys "Future Leaders in the Biotech Industry" Conference
9. ShangPharma Corporation Announces Completion of Merger
10. ReSearch Pharmaceutical Services Announces Joint Venture with Asklep in Japan
11. Pharmaceutical Manufacturing in China
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... , Sept. 2, 2014 Reportlinker.com announces ... its catalogue: Asia - Pacific Minimally ... http://www.reportlinker.com/p02353212/Asia---Pacific-Minimally-Invasive-Surgery-Spinal-Device-Market.html The growth rate of the ... device market will remain at double-digit levels throughout the ... as the future of this field. The ...
(Date:9/2/2014)... , Sept. 2, 2014 The Pharmaceutical Care ... benefit managers (PBMs), today filed a lawsuit in ... new Iowa law that restricts ... for the state,s employers and consumers.  ... by severely restricting the use of Maximum Allowable Cost ...
(Date:9/2/2014)... BARCELONA , Spanien und CALGARY, Alberta ... Vorgestellt in der "State of the ... Kardiologenverbandes 2014    Resverlogix Corp. (TSX: RVX) ... of Medical Affairs bei Resverlogix, beim Kongress des europäischen ... Spanien, einen Vortrag gehalten hat. In seinem Vortrag mit ...
Breaking Medicine Technology:Asia - Pacific Minimally Invasive Surgery Spinal Device Market 2Asia - Pacific Minimally Invasive Surgery Spinal Device Market 3Asia - Pacific Minimally Invasive Surgery Spinal Device Market 4Asia - Pacific Minimally Invasive Surgery Spinal Device Market 5Asia - Pacific Minimally Invasive Surgery Spinal Device Market 6Asia - Pacific Minimally Invasive Surgery Spinal Device Market 7Asia - Pacific Minimally Invasive Surgery Spinal Device Market 8Asia - Pacific Minimally Invasive Surgery Spinal Device Market 9Asia - Pacific Minimally Invasive Surgery Spinal Device Market 10Lawsuit Challenges Iowa Health Mandate that Forces Employers to Pay More for Prescription Drugs 2RVX-208 führt bei Patienten mit Diabetes mellitus zu einer Verringerung des relativen Risikos von gravierenden unerwünschten Herzkreislaufereignissen um 77 % 2RVX-208 führt bei Patienten mit Diabetes mellitus zu einer Verringerung des relativen Risikos von gravierenden unerwünschten Herzkreislaufereignissen um 77 % 3RVX-208 führt bei Patienten mit Diabetes mellitus zu einer Verringerung des relativen Risikos von gravierenden unerwünschten Herzkreislaufereignissen um 77 % 4RVX-208 führt bei Patienten mit Diabetes mellitus zu einer Verringerung des relativen Risikos von gravierenden unerwünschten Herzkreislaufereignissen um 77 % 5RVX-208 führt bei Patienten mit Diabetes mellitus zu einer Verringerung des relativen Risikos von gravierenden unerwünschten Herzkreislaufereignissen um 77 % 6
... DIEGO, May 4, 2011 Arena Pharmaceuticals, Inc. (NASDAQ: ... 2011 financial results after the NASDAQ Global Select Market closes ... Arena,s President and Chief Executive Officer, will host a conference ... Pacific Time) to discuss the financial results for the first ...
... ULURU Inc. (NYSE AMEX: ULU) ... with the U.S. Food and Drug Administration to obtain ... containing wound care products represent a growing segment of ... and contributes to new tissue development. Collagen dressings encourage ...
Cached Medicine Technology:Arena Pharmaceuticals to Host Business and Financial Update Conference Call and Webcast on Tuesday, May 10 2Arena Pharmaceuticals to Host Business and Financial Update Conference Call and Webcast on Tuesday, May 10 3ULURU Inc. Announces the Filing of a 510(k) Application for Altrazeal® Collagen 2
(Date:9/2/2014)... (HealthDay News) -- Complications are rare among breast ... new study indicates. However, the researchers did ... a slightly higher risk for certain complications than ... than 18,000 breast cancer patients who had a ... breast reconstruction and were followed for 30 days ...
(Date:9/2/2014)... can lay the groundwork for their own spread throughout ... send out tumor-welcoming signals, according to a new report ... 2 issue of Nature Communications , the researchers ... of so-called signaling molecules released by breast cancer cells. ... lungs and lymph nodes to produce proteins called CCL5 ...
(Date:9/2/2014)... Australia (PRWEB) September 03, 2014 Operators ... attend to millions of people annually, arranging care and ... not-for-profit and private enterprises are expected to derive $39.4 ... funding, donations and private income. Over the five years ... an annualised rate of 6.6%, including growth of 4.1% ...
(Date:9/2/2014)... (HealthDay News) -- Melatonin supplements did not reduce delirium ... new study found. Many older hospital patients experience ... disruption of their normal sleep-wake cycle. A lack of ... to delirium, but there has been little research into ... study included 378 patients, average age 84, who had ...
(Date:9/2/2014)... Steven Reinberg HealthDay Reporter ... As the Ebola outbreak continues to overwhelm health-care workers ... United States and the United Nations called on Tuesday ... outbreak of the often-fatal virus. Dr. Thomas Frieden, ... Prevention, said that without a greater global commitment in ...
Breaking Medicine News(10 mins):Health News:Complication Rates Low With Mastectomy, Breast Reconstruction: Study 2Health News:‘Prepped’ by tumor cells, lymphatic cells encourage breast cancer cells to spread 2Health News:Community Services in Australia Industry Market Research Report Now Updated by IBISWorld 2Health News:Community Services in Australia Industry Market Research Report Now Updated by IBISWorld 3Health News:More Global Help Needed to Fight Ebola Outbreak 2Health News:More Global Help Needed to Fight Ebola Outbreak 3
... metabolic syndrome in strained unions, study finds , , THURSDAY, March ... unhappy marriage may be greater for women than men, a ... "strained" unions, those marked by arguing and being angry, were ... in the contentious relationships were more likely to develop high ...
... to Educate Americans on Value of Occupational Therapy and Important Role ... ... (Vocus) March 5, 2009 -- The American Occupational Therapy Association (AOTA) ... public about the scope and value of what experts are predicting ...
... 5 Medifast, Inc. (NYSE: MED ), ... today announced the appointment of John P. Daniels and ... Directors. With the addition of Mr. Daniels and ... comprised of fourteen members, ten of which are classified ...
... ANTONIO, March 5 A plentiful, inexpensive, topical compound ... Middle Eastern and African leishmaniasis as is the standard ... one of the findings of a research team from ... Thomas Jefferson University and led by Reza ...
... March 5 CorMatrix Cardiovascular, Inc., an Atlanta-based ... matrix (ECM Technology) biomaterial devices that harness the ... announced today that it has begun its expansion ... CorMatrix(R) ECM Technology(TM) in a patient undergoing cardiac ...
... Company suspends patient enrollment and contract manufacturing, ... 5 /PRNewswire-FirstCall/ - Bradmer Pharmaceuticals Inc. (BMR.TSX), today announced ... existing cash resources. The plan is in response to ... Company,s ongoing evaluation of strategic alternatives. , As announced ...
Cached Medicine News:Health News:Bad Marriages Harder on Women's Health 2Health News:Bad Marriages Harder on Women's Health 3Health News:Nearing Centennial, Occupational Therapy Profession Launches New Brand 2Health News:Nearing Centennial, Occupational Therapy Profession Launches New Brand 3Health News:Medifast, Inc. Announces Appointment of Two Additional Independent Board Members 2Health News:Medifast, Inc. Announces Appointment of Two Additional Independent Board Members 3Health News:Medifast, Inc. Announces Appointment of Two Additional Independent Board Members 4Health News:The Texas Institute of Dermatology Team Finds Easy-to-Apply, Topical Drug Just as Good as Injectable Compound for a Disfigurating Skin Infection 2Health News:CorMatrix Cardiovascular Announces First European Implants of CorMatrix(R) ECM Technology(TM) 2Health News:Bradmer implements cash conservation plan 2Health News:Bradmer implements cash conservation plan 3
... Available in 6 popular colors ... Wide crescent shape to accommodate wheel ... exam. Strong, smooth and quiet elctro-mechanical ... top. 2 Position programmable memory Patient ...
Strong, 14 gauge steel construction for lasting quality. Locking wheels for use on carpet or tile flooring. Whisper quiet up/down movement. Easy cleaning deluxe laminated top. Three year warranty....
...
... construction for lifelong quality. Sealed hydraulic system ... movement. Soft, contoured cushions with heavy-duty upholstery ... slit lamp arm for easy, smooth, and ... lamp arm for easy access to children ...
Medicine Products: